e-learning
resources
ERJ
2007
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide
Tiev K. P., Cabane J., Aubourg F., Kettaneh A., Ziani M., Mouthon L., Duong-Quy S., Fajac I., Guillevin L., Dinh-Xuan A. T.
Source:
Eur Respir J 2007; 30: 26-30
Journal Issue:
July
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Tiev K. P., Cabane J., Aubourg F., Kettaneh A., Ziani M., Mouthon L., Duong-Quy S., Fajac I., Guillevin L., Dinh-Xuan A. T.. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J 2007; 30: 26-30
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
An increase in exhaled nitric oxide is not associated with activity in pulmonary sarcoidosis
Source: Eur Respir J 2004; 24 : 609-614
Year: 2004
Increased alveolar concentrations of exhaled nitric oxide (NO) are associated with lung affection in systemic sclerosis (SSc)
Source: Eur Respir J 2005; 26: Suppl. 49, 543s
Year: 2005
Bronchial and alveolar exhaled nitric oxide as a marker of systemic involvement in patients with Crohn‘s disease
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Elevated levels of alveolar nitric oxide in patients with inflammatory bowel disease
Source: International Congress 2016 – Airway biomarkers
Year: 2016
Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients
Source: Eur Respir J 2009; 34: 138-144
Year: 2009
Fractional exhaled nitric oxide in chronic obstructive pulmonary disease
Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease
Year: 2015
Increased exhaled nitric oxide precedes lung fibrosis in a murine model of systemic sclerosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease
Source: International Congress 2017 – ILDs: clinical problems
Year: 2017
The source of exhaled nitric oxide does not correlate with clinical markers in interstitial lung disease
Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease
Year: 2007
Fractional exhaled nitric oxide for eosinophilic inflammation in stable COPD
Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers
Year: 2017
Exhaled nitric oxide levels in patients with pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Nasal nitric oxide
Source: Eur Respir Monogr 2010; 49: 71-81
Year: 2010
Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients
Source: Eur Respir J 2001; 17: 1267-1270
Year: 2001
Fractional exhaled nitric oxide levels in patients with non-cystic fibrosis bronchiectasis
Source: International Congress 2016 – Asthma, bronchiectasis, and the risk factors for respiratory morbidity
Year: 2016
Clinical correlates of alveolar nitric oxide in COPD
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018
Exhaled nitric oxide is not reduced in infants with cystic fibrosis
Source: Eur Respir J 2006; 27: 350-354
Year: 2006
Exhaled nitric oxide increases in chronic eosinophilic pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 509s
Year: 2002
Exhaled nitric oxide and pulmonary function in children with sickle cell disease
Source: Annual Congress 2010 - Paediatric asthma, rhinitis and management
Year: 2010
Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model
Source: Eur Respir J 2006; 28: 1236-1244
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept